Salvage chemotherapy and maintenance therapy with poly adenosine diphosphate-ribose polymerase inhibitors for bevacizumab-resistant relapse of epithelial ovarian cancer

Adjuvant chemotherapy combined with bevacizumab, an angiogenesis inhibitor, can improve the survival of advanced epithelial ovarian cancer (EOC), but relapse during bevacizumab maintenance therapy may occur. Despite poly adenosine ribose-polymerase (PARP) inhibitors were shown to achieve remission in the relapsed patients upon salvage chemotherapy and long-term maintenance, there is little evidence on their efficacy or criteria for selecting bevacizumab-resistant recurrent EOC patients who would benefit from PARP inhibitors. In this single-center, retrospective, case-series study, we evaluated the efficacy, safety and selection criteria for salvage chemotherapy followed by PARP inhibitors in bevacizumab-resistant EOC patients who recurred during bevacizumab maintenance. The primary endpoint was post-progression survival (PPS), and the secondary endpoints were progression-free survival (PFS) and safety. In all, the data of 49 EOC patients, most of whom were graded as stage III (91.8%) with high-grade serous histology (81.6%), were assessed. They were classified into three groups based on platinum-free interval (PFI) and response to salvage chemotherapy: platinum-based chemotherapy followed by PARP inhibitors, platinum-based chemotherapy followed by non-PARP inhibitors, and non-platinum-based chemotherapy. Survival analysis showed the median PFS and median PPS for the platinum-based chemotherapy followed by PARP inhibitors group were 326 and 771 days, which were significantly longer than the other groups. The highly platinum-sensitive relapse (PSR) group (PFI >12 months) achieved prolonged PPS, while there was no relationship between the clinical status on salvage chemotherapy and response to PARP inhibitors. Adverse events during PARP inhibitor led to withdrawal and dose reduction in >40% of patients; however, no patients discontinued the drugs. Altogether, the study results showed that maintenance therapy using PARP inhibitor was effective and feasible for patients selected based on platinum sensitivity from bevacizumab-resistant relapsed EOC. PFI after adjuvant chemotherapy could predict bevacizumab-resistant EOC patients’ response to PARP inhibitors, which might be effective despite therapeutically insufficient salvage chemotherapy.

Bevacizumab; Poly adenosine-diphosphate ribose polymerase inhibitor; Niraparib; Olaparib; Ovarian cancer; Platinum sensitivity

[1] DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 11th ed. Wolters Kluwer: Philadelphia, PA. 2018.

[2] Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine. 2011; 365: 2484–2496.

[3] Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. Journal of Clinical Oncology. 2019; 37: 2317–2328.

[4] Sjoquist KM, Espinoza D, Mileshkin L, Ananda S, Shannon C, Yip S, et al. REZOLVE (ANZGOG-1101): a phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecologic Oncology. 2021; 161: 374–381.

[5] United States National Library of Medicine. Niraparib capsules, for oral use. United states prescribing information. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf (Accessed: 12 June 2022).

[6] United States National Library of Medicine. Olaparib tablets, for oral use. United states prescribing information. 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/ 2017/208558s000lbl.pdf (Accessed: 12 June 2022).

[7] Pujade-Lauraine E, Colombo N, Glasspool R, Asselain B, Huzarski T, Korach J, et al. OReO/ENGOT Ov-38: a phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer. Annals of Oncology. 2017; 28: V351–V352.

[8] Moubarak M, Harter P, Ataseven B, Traut A, Welz J, Baert T, et al. Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: a single institutional experience. Gynecologic Oncology Reports. 2022; 40: 100939.

[9] Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. The New England Journal of Medicine. 2016; 375: 2154–2164.

[10] Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet. Oncology. 2014; 15: 852–861.

[11] Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2017; 18: 1274–1284.

[12] Tomao F, D’Incalci M, Biagioli E, Peccatori FA, Colombo N. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality? Cancer. 2017; 123: 3450–3459.

[13] Chuang YT, Chang CL. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance. Taiwanese Journal of Obstetrics & Gynecology. 2012; 51: 336–341.

[14] Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemotherapy and Pharmacology. 2018; 81: 17–38.

[15] Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. Journal of Clinical Oncology. 2004; 22: 3120–3125.

[16] Herzog TJ, Monk BJ. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? Gynecologic Oncology Research and Practice. 2017; 4: 13.

[17] Bruchim I, Jarchowsky-Dolberg O, Fishman A. Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2013; 166: 94–98.

[18] Sisay M, Edessa D. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecologic Oncology Research and Practice. 2017; 4: 18.

[19] Matteis ED, Cormio G, Naglieri E, Scavelli C, Loizzi V, Cito P, et al. ReOL-Olaparib in the real world. A retrospective observational study to evaluate the impact of olaparib on the real-world treatment of BRCA carrier patients with recurrent ovarian cancer. European Journal of Gynaecological Oncology. 2019; 40: 759–764.

[20] Letendre L, Kiely JM, Hoagland HC. Reinduction chemotherapy for acute nonlymphocytic leukemia. Mayo Clinic Proceedings. 1984; 59: 618–621.

[21] Beltrame L, Di Marino M, Fruscio R, Calura E, Chapman B, Clivio L, et al. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Annals of Oncology. 2015; 26: 1363–1371.

[22] Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, et al. Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecologic Oncology. 2020; 156: 38–44.